title: Long-term results of immunosuppressive oral prednisone  after coronary angioplasty in non-diabetic patients with  elevated C-reactive protein levels.
abstract: OBJECTIVE
  To present the long-term results of prednisone-treated patients enrolled in the IMPRESS studies. Such studies demonstrated the efficacy of a short course of immunosuppression with oral prednisone after percutaneous coronary intervention (PCI) with bare metal stent (BMS) implantation compared to BMS alone at one year.
  
  
  RESULTS
  Eighty-four non-diabetic patients with elevated C-reactive protein after PCI treated with BMS and prednisone, were followed clinically for a minimum of five years. Event-free survival was defined as freedom from death, myocardial infarction, and need for target vessel revascularisation. Event-free survival rate at a mean of 6.5 +/- 1.4 years was significantly better in prednisone-treated patients of the IMPRESS and IMPRESS-2/MVD respectively compared to their original control arms: 87.8 versus 47.6%, relative risk: 7.9; 95%CI: 2.6-24.1, p<0.0001, log-rank=13.06, p=0.0003; and 93 versus 60.5%, relative risk: 8.7; 95%CI: 2.3-32.7, p=0.0004, log-rank=13,18, p=0.0003, respectively. The event-free survival was 54.1% in controls and 90.5% in the prednisone group; relative risk: 8.1; 95%CI: 3.5-18.7, p<0.0001, log-rank= 26.33, p<0.0001.
  
  
  CONCLUSIONS
  The clinical benefits of oral treatment with prednisone after conventional PCI in non-diabetic patients with evidence of systemic inflammation after stenting are maintained at long-term follow-up, either in patients with single or multivessel coronary artery disease.
authors.affiliation: Division of Cardiology of the Università di Verona, Verona, Italy.
authors.forename: Valeria
authors.initials: V
authors.lastname: Ferrero
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Tomai
authors.forename: Francesco
authors.initials: F
authors.lastname: Versaci
authors.forename: Mauro
authors.initials: M
authors.lastname: Feola
authors.forename: Igino
authors.initials: I
authors.lastname: Proietti
authors.forename: Andrea
authors.initials: A
authors.lastname: Rognoni
authors.forename: Anna S
authors.initials: AS
authors.lastname: Ghini
authors.forename: Achille
authors.initials: A
authors.lastname: Gaspardone
authors.forename: Giovanni
authors.initials: G
authors.lastname: Vacca
authors.forename: Leonardo
authors.initials: L
authors.lastname: De Luca
authors.forename: Corrado
authors.initials: C
authors.lastname: Vassanelli
authors.forename: Flavio
authors.initials: F
authors.lastname: Ribichini
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation / Q000401:mortality; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D016009:Chi-Square Distribution; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D018836:Inflammation Mediators / Q000097:blood*; D053208:Kaplan-Meier Estimate; D008297:Male; D008670:Metals; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control; D011241:Prednisone / Q000008:administration & dosage*; D011446:Prospective Studies; D011474:Prosthesis Design; D018570:Risk Assessment; D012307:Risk Factors; D016037:Single-Blind Method; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation
chemical_list: D015415:Biomarkers; D007166:Immunosuppressive Agents; D018836:Inflammation Mediators; D008670:Metals; D002097:C-Reactive Protein; D011241:Prednisone